BNT166a
/ BioNTech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 06, 2026
A Phase 2a Study of Safety and Exploratory Immune Responses to BNT166a, an Investigational mRNA Mpox Vaccine
(IDWeek 2026)
- No abstract available
Clinical • P2a data • Infectious Disease
1 to 1
Of
1
Go to page
1